Eribulin in Brain Metastases From HER2-negative Breast Cancer
Status: WITHDRAWN
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: Eribulin
Sponsor: Institut Paoli-Calmettes
Collaborators: Eisai Inc.